CORDIS · 116106 · H2020
IB4SD-TRISTAN Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106
Coordinator: EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE)
1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized experts in transporter biology, animal models of lung injury, toxicology, DCEMRI, compartmental modeling, 1H&129Xe lung MR, and labeling of biologicals with PET and fluorescence tags, together with physicians who care for relevant patients. We have an outstanding record of translating IBs: (a) into animals, (b) into man, (c) into tools which drug developers use with confidence in clinical trials of investigational agents, (d) into regulatory drug development…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €12.0M awarded to the consortium. The project runs over approximately 8 years from 2017-01-01 to 2024-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from BE
see all →- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · H2020 · €178.2M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · HORIZON · €153.0M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · H2020 · €150.0M
- SGA2 — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101197135 · HORIZON · €120.0M
- SGA3 — COST - Maximising impact861952 · H2020 · €81.8M
- EIT Digital BP — EIT Digital Sustainable Growth101113245 · HORIZON · €33.7M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · CH · €89.0M
- GrapheneCore1 — Graphene-based disruptive technologies696656 · SE · €89.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €12.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2015-07-two-stage.
- Who coordinates the project?
- The project is coordinated by EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE).
- What is the project timeline?
- The project runs from 2017-01-01 to 2024-12-31 — approximately 8 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 116106.